A case of schizophrenia with Parkinson's disease: Reduced dopamine transporter binding in unilateral striatum and normal uptake pattern of 123I-MIBG myocardial scintigraphy.

BACKGROUND

In rare instances, Parkinson's disease may develop in patients with schizophrenia receiving antipsychotic treatment, highlighting the need for comprehensive clinical evaluation and imaging investigations. We present a case of schizophrenia coexisting with suspected familial Parkinson's disease, characterized by a discrepancy between dopamine transportor single photon emission computed tomography (DAT SPECT) and 123I meta-iodo benzylguanidine (MIBG) myocardial scintigraphy results.

CASE PRESENTATION: The patient was a woman in her 50s who first exhibited paranoid delusions and auditory hallucinations in her 20s and was continuously treated on an outpatient basis for schizophrenia. Three years ago, she sought consultation at a neurology clinic due to resting tremor in the right upper limb and difficulty walking. Given the asymmetry of her symptoms and the notable decrease in left-sided uptake observed on the DAT SPECT, she was diagnosed with Parkinson's disease, and her symptoms improved with levodopa therapy. One year later, she developed lower limb rigidity and weakness, and was seen at another hospital's neurology department. Despite these findings, MIBG myocardial scintigraphy revealed no significant uptake reduction, leading to a diagnosis of drug-induced parkinsonism. After reducing both anti-Parkinson's and antipsychotic medications, her auditory hallucinations and motor difficulties worsened, prompting her referral to our department for inpatient care. On reassessment, Parkinson's disease was confirmed and anti-Parkinson's medication was reintroduced, leading to improvement in her motor symptoms without exacerbation of psychiatric symptoms, and she was discharged home.

CONCLUSION

Prompt and accurate diagnosis through detailed clinical evaluation and appropriate imaging studies is crucial for the effective management of both schizophrenia and parkinsonism, ensuring optimal control of both conditions. Clinical trial registration. This report is not a clinical trial.